Last reviewed · How we verify

NCT06057103: ZX-7101A-208

A Study to Evaluate Drug-drug Interaction of ZX-7101A Tablets and Oseltamivir Phosphate Capsules in Healthy Adult Subjects

Completed Phase 1 Last updated 4 November 2024
What this trial tests

Phase 1 trial testing ZX-7101A in Drug Interaction in 18 participants. Completed in 26 April 2024.

Timeline
28 August 2023
Primary endpoint
5 December 2023
26 April 2024

Quick facts

Lead sponsorNanjing Zenshine Pharmaceuticals
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment18
Start date28 August 2023
Primary completion5 December 2023
Estimated completion26 April 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Nanjing Zenshine Pharmaceuticals — full company profile →

Who can join

Adults 18 to 45, any sex, with Drug Interaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary object of this study is evaluating the effect of multiple oral oseltamivir phosphate capsules on the pharmacokinetic profile of the active metabolite ZX-7101 after a single oral administration of ZX-7101A tablet in healthy Chinese adult subjects. The seongdary object is evaluating combined or uncombined multiple oral oseltamivir phosphate in healthy Chinese adult subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ZX-7101A

Trials testing the same drug.

Other recruiting trials for Drug Interaction

Currently open trials in the same condition.

Other Nanjing Zenshine Pharmaceuticals trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06057103.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing